|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2019
gptkb:FDA
|
|
gptkbp:clinical_trial
|
Phase 3
|
|
gptkbp:contraindication
|
hypersensitivity to components
|
|
gptkbp:dosage_form
|
gptkb:tablet
gptkb:battle
|
|
gptkbp:genetic_diversity
|
F508del
A455 E
D1152 H
G1349 D
G551 D
K1060 T
L206 W
N1303 K
R1070 Q
R1070 W
R117 A
R117 C
R117 D
R117 E
R117 F
R117 G
R117 H
R117 I
R117 J
R117 K
R117 L
R117 M
R117 N
R117 O
R117 P
R117 Q
R117 R
R117 S
R117 T
R117 U
R117 V
R117 W
R117 X
R117 Y
R117 Z
R334 W
R347 H
R560 K
S1251 N
S1255 P
V520 F
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Trikafta
|
|
gptkbp:ingredients
|
gptkb:elexacaftor
gptkb:ivacaftor
gptkb:tezacaftor
|
|
gptkbp:invention
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:is_used_for
|
gptkb:cystic_fibrosis
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
rash
|